NL2034225B1 - Efficient iron supplement for pets, preparation method and application thereof - Google Patents
Efficient iron supplement for pets, preparation method and application thereof Download PDFInfo
- Publication number
- NL2034225B1 NL2034225B1 NL2034225A NL2034225A NL2034225B1 NL 2034225 B1 NL2034225 B1 NL 2034225B1 NL 2034225 A NL2034225 A NL 2034225A NL 2034225 A NL2034225 A NL 2034225A NL 2034225 B1 NL2034225 B1 NL 2034225B1
- Authority
- NL
- Netherlands
- Prior art keywords
- iron
- preparation
- pets
- mulberry
- solution
- Prior art date
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 120
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 65
- 239000013589 supplement Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 240000000249 Morus alba Species 0.000 claims description 54
- 235000008708 Morus alba Nutrition 0.000 claims description 52
- 150000004676 glycans Chemical class 0.000 claims description 51
- 239000005017 polysaccharide Substances 0.000 claims description 51
- 229920001282 polysaccharide Polymers 0.000 claims description 41
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000013522 chelant Substances 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 8
- 239000012266 salt solution Substances 0.000 claims description 8
- 239000001509 sodium citrate Substances 0.000 claims description 7
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 7
- 229940038773 trisodium citrate Drugs 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 2
- 230000009920 chelation Effects 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 230000001502 supplementing effect Effects 0.000 abstract description 6
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 36
- 102000001554 Hemoglobins Human genes 0.000 description 31
- 108010054147 Hemoglobins Proteins 0.000 description 31
- 238000012360 testing method Methods 0.000 description 31
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 150000004804 polysaccharides Polymers 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 102000008857 Ferritin Human genes 0.000 description 5
- 238000008416 Ferritin Methods 0.000 description 5
- 108050000784 Ferritin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000004820 blood count Methods 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- -1 ferric iron ions Chemical class 0.000 description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 235000019263 trisodium citrate Nutrition 0.000 description 4
- 239000003513 alkali Substances 0.000 description 3
- 238000004159 blood analysis Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 102000018146 globin Human genes 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940046545 animal allergen extract Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940078042 polysaccharide iron complex Drugs 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/22—Compounds of alkali metals
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides an efficient iron supplement for pets, a preparation method and application thereof. The efficient iron supplement for pets has a good iron supplementing effect, a high absorption rate is conducive to play a role of iron supplementing, which facilitates iron supplementing of the pets, and has broad development prospects.
Description
P1737 /NLpd
EFFICIENT IRON SUPPLEMENT FOR PETS, PREPARATION METHOD AND
APPLICATION THEREOF
The present invention relates to the technical field of pet food, in particular to an efficient iron supplement for pets, a preparation method and application thereof.
At present, inorganic iron and organic iron are the main iron supplements commonly used by pets. Although inorganic iron can al- leviate the symptoms of iron deficiency and anemia to a certain extent, inorganic iron is often accompanied by side effects such as gastrointestinal irritation and rusty taste, and has low bioa- vailability and poor chemical stability.
The objective of the present invention is to provide an effi- cient iron supplement for pets, a preparation method and applica- tion thereof. In the efficient iron supplement for pets, mulberry polysaccharide chelated ferric iron has high absorbability of che- late, facilitates iron supplementing for pets, and has stable properties, safety, no irritation and a low cost.
In order to achieve the above objective, the present inven- tion provides the following technical solution:
The efficient iron supplement for pets is provided, chemical composition is the mulberry polysaccharide chelated ferric iron, and the ferric iron is chelated in the mulberry polysaccharide by means of trisodium citrate.
The preparation method for the efficient iron supplement for pets according to the above technical solution is provided and in- cludes: mixing the mulberry polysaccharide, the trisodium citrate, water and ferric salt solution, adjusting a pH value of an ob- tained mixed solution to 8.0-9.0, and performing chelating reac-
tion to obtain a chelate product; and sequentially performing separation and purification on the chelate products to obtain the efficient iron supplement for pets.
Preferably, a mass ratio of the mulberry polysaccharide to the trisodium citrate is (3-5):1.
Preferably, a mass ratio of the mulberry polysaccharide to the water is 1: (8-12).
Preferably, a mass ratio of the mulberry polysaccharide to the ferric salt solution is 5:1-2:3; the ferric salt solution is a
FeCl; solution; and a concentration of the ferric salt solution is 2.5-3.5 mol/L.
Preferably, alkali liquor used for adjusting the pH value of the obtained mixed solution includes a sodium hydroxide solution; and a concentration of the alkali liquor is 1.5-2.5 mol/L.
Preferably, temperature of the chelating reaction is 70°C for 1 h.
Preferably, a reagent used in separation is an ethanol solu- tion, and a volume fraction of the ethanol solution is 75-85%.
Preferably, a reagent used in purification is the water, and a purification maner is dialysis; and molecular weight cut-off of a dialysis bag used for dialysis is 8000-14000 D.
The present invention provides application of the efficient iron supplement for pets according to the above technical solution or the efficient iron supplement for pets prepared by the prepara- tion method according to the above technical solution in pet food.
According to the present invention, the mulberry polysaccha- ride is used as a carrier, and match ferric iron ions to form mul- berry polysaccharide iron chelate, and the iron ions are used as a core and are wrapped in a middle of the polysaccharide by means of hydroxyl groups and carboxyl groups, which leads to morphology of the polysaccharide changing from a flat shape to a rod shape; and due to the ring structure, the mulberry polysaccharide chelated ferric iron has higher stability, and high water solubility in ac- id and alkali environments. Moreover, the iron ions are chelated in the mulberry polysaccharide, the mulberry polysaccharide che- lated ferric iron does not contain any free iron ions, enters cells in a small molecular state, does not compete with other nu-
trient elements for absorption channels, has a higher absorption rate, and reduces adverse reactions such as gastrointestinal tract irritation caused by the free iron ions compared with ferrous sul- fate. Further, the mulberry polysaccharide has many physiological activities, such as improving immunity, antioxidation, anti-tumor, etc., after the iron in the mulberry polysaccharide-iron chelate is released, the polysaccharide may continue to exert other medic- inal effects. Therefore, the mulberry polysaccharide chelated fer- ric iron provided by the present invention may be used as the iron supplement to treat iron deficiency anemia, and may also resist oxidation and improve immunity of the organism. Therefore, the present invention utilizes the function of the polysaccharide to promote mineral absorption, and the provided mulberry polysaccha- ride chelated ferric iron may be used as the iron supplement with high bicavailability, such that the mulberry polysaccharide-iron chelate may not only supplement iron in daily life for health care, but also treat the iron deficiency anemia, thus achieving dual functions of health care and treatment.
Example 1 8 g of mulberry polysaccharide raw material and 2 g of triso- dium citrate were dissolved in 80 mL of distilled water, 4 mL of ferric chloride solution having a concentration of 3 mol/L (1.94 g) was added dropwise, pH was adjusted to 8.5 with a NaOH solution having a concentration of 2 mol/L, an obtained mized solution was reacted with a magnetic stirrer at 70°C for 1 h, and an obtained product solution was centrifuged with a centrifuge at 4000 r/min for 5 min, and the precipitate was removed to obtain supernatant; an ethanol solution having a volume fraction of 80% was added into the supernatant, standing was performed for 12 h, the super- natant was discarded, precipitate was collected, and the precipi- tate was washed once with the ethanol solution having the volume fraction of 80% to obtain crude mulberry polysaccharide-iron; and the crude mulberry polysaccharide-iron was dissolved in puri- fied water, water dialysis was performed to remove salt, molecular weight cut-off of a dialysis bag was 12000 D, the crude mulberry polysaccharide-iron without salt was ethanol precipitated with the ethanol solution having the volume fraction of 80% for 36 h, and drying was performed at 60°C to obtain mulberry polysaccharide chelated ferric iron.
Examples 2-5
The only difference between Examples 2-5 and Example 1 is that volume of a ferric chloride solution is 6 mL, 8 mL, 10 mL and 12 mL in sequence.
Verification and testing 1) A stability test
A test method: the stability test for mulberry polysaccharide chelated ferric iron includes a water solubility test and a dis- coloration test. The mulberry polysaccharide chelated ferric iron prepared in Examples 1~5 are numbered 1, 2, 3, 4, 5 in sequence.
Test tubes having a capacity of 10 mL are numbered 1-1, 1-2, 1-3, 1-4, 1-5, 2-1, 2-2, 2-3, 2-4, 2-5. 8mL of distilled water is added into the test tubes numbered 1-1, 1-2, 1-3, 1-4, 1-5 separately. 1 g of mulberry polysaccharide chelated ferric iron numbered 1, 2, 3, 4, 5 are weighed separate- ly, the samples are added into the test tubes numbered 1-1, 1-2, 1-3, 1-4, 1-5 to observe solubility of the samples, with results seen in Table 1.
Table 1 Water solubility test
The results in Table 1 show that the mulberry polysaccharide chelated ferric iron samples in Examples 1-5 have stable proper- ties and may be well dissolved in water. 8mL of distilled water is added into the test tubes numbered 2-1, 2-2, 2-3, 2-4, 2-4, 2-5 separately. 1 g of mulberry polysac- charide chelated ferric iron numbered 1, 2, 3, 4, 5 are weighed, the samples are added inte the test tubes numbered 2-1, 2-2, 2-3, 2-4, 2-5 separately, a potassium ferrocyanide solution was slowly dropwise added, the test tube are shaken to observe phenomena, with results seen in Table 2.
Table 2 Discoloration test
Without precipitation and other changes
Without precipitation and other changes
Without precipitation and other changes
Without precipitation and other changes
Without precipitation and other changes 2) Iron content testing 5 The iron content is tested in the samples of mulberry poly- saccharide chelated ferric iron prepared in Examples 1-5 according to a method described in Table 3, with results seen in Table 3.
Table 3 Results of iron content testing
Mainly use in-
Sample State Testing basis Testing results struments . Total iron (Fe)
Example 1 Brown powder | Kjeldahl appa- . 68997.67 mg/kg ratus, ultraviolet spectrophotome-
Total iron {Fe}
Example 2 Brown powder ter, flame pho- tometer, atomic | NY 884-2012, NY 525- 220573.69 mg/kg absorption spec- | 2021, N/Y 798-2004, trometer, induc- | GB/T 19524.1-2004, GB/T | Total iron (Fe)
Example 3 Brown powder tively coupled 19524.2-2004, N/Y 1978- | 229462.51 mg/kg plasma emission | 2010
Total iron {Fe) spectrometer,
Example 4 Brown powder . 200864.94 electronic bal- mg/k ance, pH meter g/kg and amino acid .
Total iron (Fe)
Example 5 Brown powder analyzer 207563.30 mg/kg
Testing unit: Nanjing Sinong testing co, itd 3) Mouse test
Testing animals: 80 newly weaned SD big rats in half male and half female with weight of 70 + 10 g, and hemoglobin Hb not less than 120 g/L.
Preparation of iron deficiency anemia models in the big rats: the male and female big rats are kept in plastic cages separately without bedding, and a feeding environment is strictly prevented from iron pollution. With reference to a low-iron feed formula recommended by AOAC, Association of Official Analytical Chemists, low-iron basic feed is prepared, the formula is as follows: corn starch, brown sugar, choline oxide, mixed vitamins and trace ele- ments in a ratio of 95:4.7:0.1:0.1:0.1 (a mass ratio). Average iron content of the low-iron basic feed is determined to be 12.16 mg/kg with atomic absorption spectrometry. Further, a tail-cutting method is used for bleeding the rats at a frequency of 3 times a week and amount of 1.5 mL of blood each time for 8 weeks. During an experiment, the animals freely eat the low-iron feed and deion- ized water. The hemoglobin is tested at the end of 8" week, and big rats with the hemoglobin lower than 60 g/L are selected as the iron deficiency anemia models.
Grouping and administration: the big rats with iron deficien- cy anemia models are randomly divided into 5 groups, including a model group (N.S), a positive control group (a polysaccharide-iron complex capsule with 25.00 mg iron/kg), a group with high dose of mulberry polysaccharide chelated ferric iron (the mulberry poly- saccharide chelated ferric iron according to Example 3 with 50.00 mg iron/kg), a group with middle dose of mulberry polysaccharide chelated ferric iron (the mulberry polysaccharide chelated ferric iron according to Example 3 with 25.00 mg iron/kg), and a group with low dose of mulberry polysaccharide chelated ferric iron (the mulberry polysaccharide chelated ferric iron according to Example 3 with 12.5 mg iron/kg), with 10 rats in each group. All the ani- mals are given drugs by gavage once a day for 4 weeks continuous- ly. Animal condition observation: before and the day after the last drug giving, tails are cut to take blood, and the hemoglobin, red blood cell count, hematocrit, serum ferritin, erythropoietin and serum iron are tested to observe recovery of the iron defi- ciency anemia in the big rats.
Test results are as follows:
Results of testing indexes in 0°" week and 4" week in Table 4.
Table 4 Results of testing indexes in 0" week and 4" week
Group with Group with
Group with high middie dose tow dose of dose of mulber-
Positive control! of mulberry mulberry
N.S group ty polysaccha- group polysaccha- polysaccha- ride chelated ride chelated ride chelated ferric iron Pp
Index P value P value Pvalue ferric iron Pvalue ferric iron value 0 4 0 4 4 0 4 4 0 week week 0 weeks week week weeks weeks weeks weeks weeks s s s s
Hemo- 55.69 52.45 53.74 82.47
P= 56.26 + 149.55 P< 54.15 + 152.33 P< 151.23 P< 55.94 + P< globin £ t t + 0.05 0.91 +277 0.05 1.55 +341 0.05 +3.81 0.05 0.57 0.05 (g/l) 1.10 1.24 0.87 0.50
Red blood 5.06 4.98 5.04 6.24 cel Pz 509+ 7.13% P< 498+ 7.21 P< 7.10% P< 5.11 P< + + + + count 0.05 0.23 0.45 0.05 0.19 0.32 0.05 0.66 0.05 0.42 0.05 0.15 0.12 0,39 0.56 {x 10")
Hema- 22.50 21.12 21.98 33.88 p> 2187+ 38.25t P< 22.13% 4145+ P< 3955+ P< 2108+ P< tocrit + + + + 0.05 0.81 1.21 0.05 0.69 1.02 0.05 0.93 0.05 0.66 0.05 (%) 0.76 0.69 0.86 0.82
Serum 208.2 204.9 206.6 232.9 ferritin Pz 207.061 264.08 P< 210.44 269.76 P< 265.08 P< 210,65 P< it Bt 7% 5+ (ng/mL 0,05 21.07 +31.29 0.05 +23.89 £33.44 0.05 +3527 0.05 124.28 0.05 22.23 19.34 26.23 34.12
EPO 2.18 2.19 2.19 6.55
Pz 223+ 812% P< 226% 832% P< 814+ P< 227+ P< {mU/m + + + + 0.05 0.61 0.76 0.05 0.57 0.59 0.05 0.55 0.05 0.43 0.05
L) 0.50 0.43 0,59 0.87 6.38 6.13 6.24 26.33
Serum P2 667+ 36.29% P< 692+ 38.21t P< 37.08% P< 6,471 P< + + t + iron 0.05 2.28 4.98 0.05 3.14 6.02 0.05 5.21 0,05 2.36 0.05 1.82 2.01 0.27 3.29
Results of testing indexes of groups in 4% week in Table 5.
Table 5 Results of testing indexes of groups in 4% week
Group with Group with
Group with high dose of middle dose low dose of
Positive mulberry of mulberry mulberry index N.Sgroup control polysaccha- polysaccha- P value polysaccha- group ride chelat- ride chelat- ride chelated ed ferric ed ferric ferric iron iron iron
Hemoglobin 52.45 + 149.55 + 152.33 ¢ 151.23 + 0 ‚ / 82.47 £0.50 P< 0.05 (g/L) 1.24° 2.77° 3.41° 3.81°
Red blood cell 4.981 7.13% i b 1 7.21+0.32° 7.10+0.66° 6.24+0.56 P<0.05 count {x 10“/L) 0.12° 0.45° 21.12 38.251 414514 39.55% b
Hematocrit {3%} ) . / . 33.88 + 0.82 P<0.05 0.69 1.21 1.02° 0.93
Serum ferritin 204.98 + 264.08 + 269.76 + 265.08 + 232.95 +
P<0.05 (ng/mL) 19.34° 31.29 33.44° 35.27 34.12° 2.19 8.12 + ij
EPO (mU/mL) 8.32+059 8.14+0.55 6.5510.87 P<0.05 0.43° 0.76° 6.13 + 36.29 + 38.21 + 37.08 + b
Serum iron / A 26.33+3.29 P< 0.05 2.01° 4.98 6.02° 5.21°
It may be seen from Table 5, compared with the N.S control group, the hemoglobin, the red blood cell count, the hematocrit, the serum ferritin, the erythropoietin (EPO) and the serum molten iron of the test rats of the positive control group and the groups with different doses of mulberry polysaccharide chelated ferric iron increase significantly (P < 0.05), and results of the posi- tive control group, the group with high doses of mulberry polysac- charide chelated ferric iron, and the group with middle doses of mulberry polysaccharide chelated ferric iron are significantly better than those of the group with low doses of mulberry polysac- charide chelated ferric iron (P < 0.05). Results of the serum fer- ritin and serum iron levels show that the group with high doses of mulberry polysaccharide chelated ferric iron and the group with middle doses of mulberry polysaccharide chelated ferric iron have a high absorption rate in test rats. 4) Pet cases
Example 1: Nana, a 4-year-old golden retriever with weight of
27.3 kg, is emaciated and mentally ill in late pregnancy, is diag- nosed as iron deficiency anemia in a pet hospital, and because of mild illness, an owner may only give Nana iron supplements during daily feeding.
Example 2: Xiaoxiao, a 2-year-old Teddy dog with weight of 3 kg, is found by an owner to have poor appetite and inactivity dur- ing pregnancy, the hemoglobin is found to be lower than a normal value during blood examination in the pet hospital, and Xiaoxiao is finally diagnosed as the iron deficiency anemia.
Example 3: Baixue, a 2-year-old bichon frise with weight of 4 kg, is weak at the beginning of pregnancy, with messy and dull hair, and is diagnosed as the iron deficiency anemia after being checked out in the pet hospital.
Test animals: Due to the individual differences of mammali- ans, the three bitches with different breeds and weights and the iron deficiency anemia during pregnancy are selected as test mod- els.
Test period: 30 days
Test design: the three dogs are divided into three groups, and the mulberry polysaccharide chelated ferric iron prepared in
Example 3 is supplemented under the condition that the original feeding conditions are unchanged.
Group A: Nana, who is fed with samples of the mulberry poly- saccharide chelated ferric iron according to amount of 15 mg/kg body weight per day.
Group B: Xiaoxiao, who is fed with samples of the mulberry polysaccharide chelated ferric iron according to amount of 15 mg/kg body weight/day.
Group C: Nana, who is fed with samples of the mulberry poly- saccharide chelated ferric iron according to amount of 15 mg/kg body weight/day.
Blood examination is performed in the pet hospital on the 0%, 10%, 20% and 30% day separately to test the effect of iron sup- plementing, with results seen in Table &.
Table 6 Results of routine blood examination in groups A, B and C
Day 10d 20d 30d
Group
The hemoglobin
A hemoglobin value is | The hemoglobin value The hemoglobin value is value is normal, the low, the red blood cell | increases, the red blood normal, the red blood red blood cell count is count is reduced, and | cell count increases, and | cell count is normal, and
A normal, and the a concentration of the | the concentration of the | the concentration of the concentration of the hemoglobin is not up hemoglobin is not up to hemoglobin is up to hemoglobin is up to to standard. standard. standard. standard.
The hemoglobin
The hemoglobin value | The hemoglobin value The hemoglobin value value increases, the is low, the red blood increases, the red blood increases, the red blood red blood cell count cell count is reduced, cell count increases, and | cell count increases, and increases, and the and the concentration | the concentration of the | the concentration of the concentration of the of the hemoglobin is hemoglobin is not up to hemoglobin is not up to hemoglobin is up to not up to standard. standard. standard. standard.
The hemoglobin
The hemoglobin value | The hemoglobin value The hemoglobin value value is normal, the is low, the red blood increases, the red blood increases, the red blood red blood cell count is cell count is reduced, cell count increases, and | cell count increases, and
C normal, and the and the concentration | the concentration of the | the concentration of the concentration of the of the hemoglobin is hemoglobin is not up to hemoglobin is up to hemoglobin is up to not up to standard. standard. standard. standard.
Table 6 shows that after 30 days, the dogs of the group A and the group C with the iron deficiency anemia have completely recov- ered, and the dog of the group B gradually recovers, which show that the mulberry polysaccharide chelated ferric iron provided by the present invention has a good effect on daily iron supplement- ing and health care and treatment of the iron deficiency anemia.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2034225A NL2034225B1 (en) | 2023-02-27 | 2023-02-27 | Efficient iron supplement for pets, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2034225A NL2034225B1 (en) | 2023-02-27 | 2023-02-27 | Efficient iron supplement for pets, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL2034225B1 true NL2034225B1 (en) | 2024-09-05 |
Family
ID=92761873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2034225A NL2034225B1 (en) | 2023-02-27 | 2023-02-27 | Efficient iron supplement for pets, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| NL (1) | NL2034225B1 (en) |
-
2023
- 2023-02-27 NL NL2034225A patent/NL2034225B1/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL2034225B1 (en) | Efficient iron supplement for pets, preparation method and application thereof | |
| CN112970948A (en) | Nutritional hematopoietic functional feed additive and preparation method thereof | |
| CN106243176A (en) | The copper complex formazan preparation method of sucrose | |
| Alexandrova et al. | Influence of Termovet and Prodactive Acid SE preparations on blood parameters of broiler chickens | |
| CN102090544B (en) | Selenium-rich goose feed and method for improving organic selenium in goose bodies | |
| US6313170B1 (en) | L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof | |
| RU2521369C1 (en) | Agent or stimulation of metabolic processes, prevention and treatment of gastrointestinal diseases in calves in early postnatal period | |
| CN103053807B (en) | Water-soluble composite vitamin preparation and preparation method thereof | |
| EP1536699A2 (en) | Use of metal chelates in human or animal feeding | |
| CN107373144B (en) | Zinc fumarate complex and preparation method and application thereof | |
| CN103622979A (en) | Preparation method of iron sucrose bulk drug and injection | |
| CN116138357A (en) | Feed additive for pets and preparation method and application thereof | |
| CN107467373A (en) | A kind of complex compound of secondary complex copper and its production and use | |
| RU2704033C1 (en) | Pharmacological composition based on water-soluble polymetal complexes of polygalacturonic acid, stimulating hematopoiesis process | |
| CN110090218B (en) | Use of chlorophyll derivatives for improving muscle microcirculation disorders | |
| CN101584687A (en) | Application of alfa-ketoglutaric acid iron in preparing iron-filling drug and health care product | |
| Miltenburg et al. | Mucosal uptake, mucosal transfer and retention of iron in veal calves | |
| US20070231383A1 (en) | Time-release compositions for delivery of [Cr3O(carboxylate)6(H2O)3]+ | |
| RU2554767C2 (en) | Medication for stimulation of metabolic processes and growth activity of calves | |
| CN105236469B (en) | The preparation method and applications of selenous acid cu zn | |
| CN111298099A (en) | Iron-supplementing composition and preparation method and application thereof | |
| Balakirev et al. | iron deficiency anemia in laboratory rats to be used as an experimental model for farmed fur-bearing animals | |
| CN115702933B (en) | Composition for assisting in reducing blood sugar | |
| CN102258535B (en) | Method for preparing veterinary compound iron dextran injection and influence of veterinary compound iron dextran injection on growth of mice | |
| Kostiushkevych et al. | Iron deficiency anemia in swine: pathogenesis, diagnosis, and preventive measures |